- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
For Drugs, the Launches Are Getting Harder, Longer | Asembia 2024
Newly launched drugs coming are facing payer controls and other hurdles, says Luke Greenwalt, vice president, market access, at IQVIA.
In an interview conducted before his presentation at Asembia 2024 meeting on April 29, Luke Greenwalt, M.D., vice president, market access, of IQVIA, discussed trends in drug launches.
The "launch window" when a drug company gets a drug established on the market and recoups the expense of developing the drug, is now 24-36 months instead of 12-18 months, Greenwalt said.
One of the reasons is "payer control," Greenwalt said: "Payer control continues to be very high for all launch products, no exception."
Payer control, he explained, is the ability of payers to restrict access to new launch products.
The mechanisms used include prior authorization, step edits, formulary exclusion and cost sharing.
Greenwalt said slower physician adoption of newly drugs is another reason for longer launch windows and navigation of payer control is one reason for that. A third factor he mentioned is "patient activation."
GLP-1 Tiering Agreement Reached, Says Optum Rx President
May 3rd 2024Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,
Read More
Specialty Pharmacies Drive Cost Savings in Value-Based Care | Asembia 2024
May 2nd 2024Earlier this week at the 2024 Asembia Specialty Pharmacy Summit in Las Vegas, Managed Healthcare Executive editors spoke with Bill McElnea, vice president of population health at Shields Health Solutions, about specialty pharmacies reducing costs for patients.
Read More
